GlassScriptPhysician profile
Dipesh Uprety
NPI 1902245269
$21,021.25
in general payments reported to CMS, 2019-2025
15 companies · $11K in 2025
The $11K reported for 2025 was more than what 81% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,281 · 2022: $6,092 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $38.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,610.00 |
| Food and Beverage | $38.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,730.00 | 2025 | |
| Eli Lilly and Company | $4,438.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $4,110.00 | 2021-2022 | |
| Genzyme Corporation | $2,416.00 | 2022 | |
| Daiichi Sankyo INC. | $2,226.25 | 2021 | |
| Jazz Pharmaceuticals INC. | $1,590.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,480.00 | 2025 | |
| Genentech USA, INC. | $31.00 | 2022 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dipesh Uprety listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.